Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8238242 | 0.87 | SLC6A3 (0.39) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5048028 | 0.82 | ALDH1A1 (0.43) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4277413 | 0.80 | NPC1 (0.45) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4283097 | 0.79 | GRM7 (0.44) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4272103 | 0.77 | CACNA2D1 (0.65) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4275669 | 0.77 | NPC1 (0.40) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL4279035 | 0.74 | GPR119 (0.44) | ALDH1A1NPC1 | |
| SCHEMBL13701595 | 0.74 | KMT2A (0.41) | ALDH1A1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL10958182 | 0.73 | HPGD (0.51) | ALDH1A1NPC1SLC6A3 | |
| SCHEMBL27407208 | 0.72 | SMN1; SMN2 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| WO-2007071035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | ALDH1A1 3323/4885CACNA2D1 45/4885CACNA1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.